STAT January 6, 2025
Readouts are coming from Ultragenyx, Akero Therapeutics, and Incyte
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:
Osteogenesis imperfecta, or OI, is a group of genetic disorders characterized by decreased bone mass and increased bone fragility. Ultragenyx is developing...